Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more
Galapagos NV (GLPGF) - Total Liabilities
Latest total liabilities as of September 2025: $1.25 Billion USD
Based on the latest financial reports, Galapagos NV (GLPGF) has total liabilities worth $1.25 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Galapagos NV - Total Liabilities Trend (2004–2024)
This chart illustrates how Galapagos NV's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Galapagos NV Competitors by Total Liabilities
The table below lists competitors of Galapagos NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Koh Young Technology Inc
KQ:098460
|
Korea | ₩62.23 Billion |
|
Perpetual Ltd
AU:PPT
|
Australia | AU$1.77 Billion |
|
Coastal Financial Corp
NASDAQ:CCB
|
USA | $4.25 Billion |
|
China Sports Industry Group Co Ltd
SHG:600158
|
China | CN¥2.47 Billion |
|
HeiLongJiang Kingland Technology Co Ltd
SHE:000711
|
China | CN¥603.48 Million |
|
Caida Securities Co Ltd
SHG:600906
|
China | CN¥41.86 Billion |
|
Terveystalo Oy
HE:TTALO
|
Finland | €854.50 Million |
|
InventisBio Co. Ltd. A
SHG:688382
|
China | CN¥94.87 Million |
Liability Composition Analysis (2004–2024)
This chart breaks down Galapagos NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galapagos NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galapagos NV (2004–2024)
The table below shows the annual total liabilities of Galapagos NV from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.24 Billion | -20.68% |
| 2023-12-31 | $1.56 Billion | -29.28% |
| 2022-12-31 | $2.21 Billion | -13.39% |
| 2021-12-31 | $2.55 Billion | -16.33% |
| 2020-12-31 | $3.05 Billion | -4.56% |
| 2019-12-31 | $3.19 Billion | +1317.53% |
| 2018-12-31 | $225.25 Million | -17.88% |
| 2017-12-31 | $274.29 Million | -15.51% |
| 2016-12-31 | $324.64 Million | +318.81% |
| 2015-12-31 | $77.52 Million | +20.49% |
| 2014-12-31 | $64.33 Million | -46.50% |
| 2013-12-31 | $120.24 Million | +2.87% |
| 2012-12-31 | $116.88 Million | +173.86% |
| 2011-12-31 | $42.68 Million | -6.11% |
| 2010-12-31 | $45.45 Million | +30.49% |
| 2009-12-31 | $34.83 Million | +0.96% |
| 2008-12-31 | $34.50 Million | -31.13% |
| 2007-12-31 | $50.10 Million | -13.78% |
| 2006-12-31 | $58.10 Million | +184.45% |
| 2005-12-31 | $20.43 Million | +289.38% |
| 2004-12-31 | $5.25 Million | -- |